Premium
Antiplatelet and invasive treatment in patients with glucose‐6‐phosphate dehydrogenase (G6 PD ) deficiency and acute coronary syndrome. The safety of aspirin
Author(s) -
Kafkas N. V.,
Liakos C. I.,
Mouzarou A. G.
Publication year - 2015
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12262
Subject(s) - medicine , aspirin , conventional pci , acute coronary syndrome , ticagrelor , glucose 6 phosphate dehydrogenase deficiency , cardiology , percutaneous coronary intervention , stent , clopidogrel , drug , myocardial infarction , pharmacology
Summary What is known and objective Aspirin is an important drug in acute coronary syndromes ( ACS ) and percutaneous coronary interventions ( PCI ). However, its use is contraindicated in patients with glucose‐6‐phosphate dehydrogenase (G6 PD ) deficiency (risk for haemolytic anaemia). We report the management of 2 patients with class II G6 PD deficiency and non‐ ST ‐segment elevation ACS ( NSTE ‐ ACS ). Case description The two patients were safely and efficiently treated with dual antiplatelet treatment ( DAPT , aspirin plus ticagrelor) and PCI using new‐generation drug‐eluting stent ( DES ) despite G6 PD deficiency. What is new and conclusion NSTE ‐ ACS management with DAPT and DES is probably safe and effective in class II G6 PD ‐deficient patients.